Zai Lab Limited American Depositary Shares (ZLAB) Stock Price
ZLABStock
$26.08−17.46%52W
Market Cap$2.93B
P/E—
PEG Ratio—
Div yield—
Beta0.46
ZLAB Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)24.48%
Price vs S&P 500 (4W)42.87%
VGM Score58.14
ZLAB Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.68 | -$0.46 | +32.29%(+$0.22) | |
| Q1 2026 | -$0.53 | -$0.46 | +12.57%(+$0.07) | |
| Q4 2025 | -$0.42 | -$0.46 | -8.45%(-$0.04) | |
| Q3 2025 | -$0.29 | -$0.33 | -12.87%(-$0.04) | |
| Q2 2025 | -$0.42 | -$0.37 | +10.85%(+$0.05) |
ZLAB Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
3.93
3.93
3.93
3.93
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ZLABZai Lab Limited American Depositary Shares | C | C | B | $26.08 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Zai Lab Limited American Depositary Shares
Zai Lab is a biopharmaceutical company developing proprietary therapeutics in oncology, autoimmune disease, and infectious disease. The company's clinical pipeline is focused on targeted antibody-drug conjugates, including programs for solid tumors, small cell lung cancer, and neuroendocrine cancers. Key candidates include ZL-1218, ZL-1310, ZL-6301, and ZL-6201, addressing multiple tumor types with novel mechanisms of action.